Blocking CB1 receptors in blood vessels may prevent heart disease

This groundbreaking study reveals how the endothelial CB1 receptor—a component of the body's cannabinoid system located in blood vessel linings—plays a harmful role in atherosclerosis development. Researchers found that this receptor is activated in atheroprone blood vessel regions and promotes vascular inflammation, increased vessel permeability, and harmful cholesterol uptake. By blocking or deleting endothelial CB1 in mice, scientists significantly reduced atherosclerosis progression, suggesting that peripheral CB1 antagonists (drugs that block CB1 without affecting the brain) could offer therapeutic potential for cardiovascular disease and metabolic dysfunction.

The study demonstrates that CB1 blockade works by reducing caveolin-1 and ALK1 expression, which decreases the vessel's ability to absorb harmful lipids. Importantly, the anti-atherosclerotic benefits were more pronounced in female subjects, possibly through interactions with estrogen signaling. The treatment also improved metabolic parameters in adipose tissue and the liver, indicating that peripheral CB1 antagonism offers dual benefits—protecting cardiovascular health while improving overall metabolic health.

These findings have significant implications for developing sex-aware cannabis therapies and understanding why peripheral CB1 targeting might help patients with metabolic disease and cardiovascular risk factors. Rather than affecting the brain like THC, future treatments could specifically block CB1 in the body's peripheral tissues, offering cardiovascular protection without central nervous system effects.